M
Melissa Nel
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
Jun 25, 2026
Governing the Genome: Whose Data, Whose Benefit?
21:01
21:31
21:51
22:21
22:27
22:44

Erin KinghornHOST
final answer or to to get your result and show your result and like you mentioned i think you said your academic quest or something like that for the for the journal articles um so i think it is important to just consider you know the aftermath of what you've what you've done and i wonder if it is important to think about in the beginning when you're sort of applying for your initial approval is that something that's currently done melissa do you have any perspective on that

Melissa NelGUEST
Yes, I mean that is something that we think about and engage with and in our information that we share with potential participants that we have outlined a clear plan for what it is that we propose to do with the findings.

Melissa NelGUEST
Yeah, I think that's particularly in the rare disease community, which I engage with as a researcher, there is a potential for individual results that we might obtain through the research process being beneficial to individual participants.

Melissa NelGUEST
with the help of a genetic counselor who I know you've also spoken with on other episodes.

Melissa NelGUEST
But potentially for the majority, because rare diseases are so rare, there is a strength in numbers and in trying to collectively study diseases from many different individuals in order to try and uncover answers.

Melissa NelGUEST
And in that way, the contribution is unlikely to generate any individual level results for the research participant, but may benefit individuals with the same disease that they have in communities, etc.
11 MINS LATER